Please assess the completion status of the following clinical trial:

Trial Title: Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant recipients at Washington University/Barnes-Jewish Hospital~2. Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant~3. On standard immunosuppression with tacrolimus and prednisone~Exclusion Criteria:~1. Dual organ or kidney after another solid organ transplant~2. Presence of a preexisting significant GI condition that does not have a presumed causal relationship with MPA~3. Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA~4. Estimated glomerular filtration rate (eGFR) \<40 ml/min at time of possible conversion~5. Proteinuria \>1 gram/day at time of possible conversion~6. Profound bone marrow suppression at the time of possible conversion as defined as:~   * Hemoglobin \<10 g/dL~  * White blood cell (WBC) \< 3 K/cumm~  * Platelets \<100 K/cumm~7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound infection, incisional hernia, lymphocele, seroma)~8. Elevated total cholesterol (\>350 mg/dL) and/or triglycerides (\>500 ng/dL) at time of possible conversion~9. Hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (EVR) (Type: ACTIVE_COMPARATOR): Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
- Prior Agent (MPA) (Type: ACTIVE_COMPARATOR): Patient will have baseline data collected while on MPA for comparison with EVR

Based on this trial design, predict the completion outcome and termination type (if applicable).